fotemustine fotemustine fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma. it is available in europe but has not been approved by the united states fda. a study has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. median survival was 7.3 months with fotemustine versus 5.6 months with dtic (p=.067). there was also toxicity prevalence in fotemustine arm. the main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with dtic) and thrombocytopenia (43% v 6%, respectively). fotemustineclinical datatrade namesmustophoranahfs/drugs.cominternational drug namespregnancycategory au: d atc codel01ad05 (who) legal statuslegal status au: s4 (prescription only) identifiers iupac name (rs)-diethyl (1-ethyl)phosphonate cas number92118-27-9 npubchem cid104799drugbankdb04106 nchemspider94600 yuniigq7jl9p5i2keggd07255 ychemblchembl549386 yecha infocard100.158.792 chemical and physical dataformulac9h19cln3o5pmolar mass315.69 g·mol−13d model (jsmol)interactive image smiles o=p(occ)(occ)c(nc(=o)n(n=o)cccl)c inchi inchi=1s/c9h19cln3o5p/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8h,4-7h2,1-3h3,(h,11,14) ykey:yakwpxvtigtrjh-uhfffaoysa-n y ny (what is this?) (verify)